Neuroligin-3 in dopaminergic circuits promotes behavioural and neurobiological adaptations to chronic morphine exposure.
dopamine
morphine
neuroligin-3
opioid
sensitization
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
30
09
2022
received:
04
04
2022
accepted:
12
10
2022
entrez:
28
12
2022
pubmed:
29
12
2022
medline:
31
12
2022
Statut:
ppublish
Résumé
Chronic opioid exposure causes structural and functional changes in brain circuits, which may contribute to opioid use disorders. Synaptic cell-adhesion molecules are prime candidates for mediating this opioid-evoked plasticity. Neuroligin-3 (NL3) is an X-linked postsynaptic adhesion protein that shapes synaptic function at multiple sites in the mesolimbic dopamine system. We therefore studied how genetic knockout of NL3 alters responses to chronic morphine in male mice. Constitutive NL3 knockout caused a persistent reduction in psychomotor sensitization after chronic morphine exposure and change in the topography of locomotor stimulation produced by morphine. This latter change was recapitulated by conditional genetic deletion of NL3 from cells expressing the Drd1 dopamine receptor, whereas reduced psychomotor sensitization was recapitulated by conditional genetic deletion from dopamine neurons. Without NL3 expression, dopamine neurons in the ventral tegmental area exhibited diminished activation following chronic morphine exposure, by measuring in vivo calcium signals with fibre photometry. This altered pattern of dopamine neuron activity may be driven by aberrant forms of opioid-evoked synaptic plasticity in the absence of NL3: dopamine neurons lacking NL3 showed weaker synaptic inhibition at baseline, which was subsequently strengthened after chronic morphine. In total, our study highlights neurobiological adaptations in dopamine neurons of the ventral tegmental area that correspond with increased behavioural sensitivity to opioids and further suggests that NL3 expression by dopamine neurons provides a molecular substrate for opioid-evoked adaptations in brain function and behaviour.
Identifiants
pubmed: 36577719
doi: 10.1111/adb.13247
pmc: PMC9803875
mid: NIHMS1842722
doi:
Substances chimiques
Morphine
76I7G6D29C
neuroligin 3
0
Dopamine
VTD58H1Z2X
Analgesics, Opioid
0
Nerve Tissue Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13247Subventions
Organisme : NIMH NIH HHS
ID : F30 MH124404
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007234
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA048742
Pays : United States
Organisme : NIDA NIH HHS
ID : F30 DA052109
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA048946
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA037279
Pays : United States
Informations de copyright
© 2022 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Nature. 2011 Dec 07;481(7379):71-5
pubmed: 22158102
J Neurosci. 2006 May 24;26(21):5720-6
pubmed: 16723528
Front Neurosci. 2016 Feb 05;10:20
pubmed: 26903789
Nature. 2007 Apr 26;446(7139):1086-90
pubmed: 17460674
J Neurosci. 2001 Jan 1;21(1):305-13
pubmed: 11150348
Neural Plast. 2018 Feb 20;2018:9803764
pubmed: 29675039
Nature. 2020 Aug;584(7820):252-256
pubmed: 32760004
Psychopharmacology (Berl). 1990;101(3):332-7
pubmed: 2163538
Cell. 2015 Jul 30;162(3):635-47
pubmed: 26232229
Mol Psychiatry. 2021 Jun;26(6):1846-1859
pubmed: 32366954
Br J Pharmacol. 2017 Aug;174(16):2716-2738
pubmed: 28585320
J Psychopharmacol. 2010 Jun;24(6):875-80
pubmed: 19164501
Cell. 2017 Nov 2;171(4):745-769
pubmed: 29100073
Neuron. 2011 Jun 9;70(5):863-85
pubmed: 21658581
Neuropsychopharmacology. 2020 Oct;45(11):1781-1792
pubmed: 32079024
Nat Neurosci. 2009 Apr;12(4):393-5
pubmed: 19270687
J Neurosci. 2021 Sep 22;41(38):7965-7977
pubmed: 34301826
Biol Psychiatry. 2011 Jun 1;69(11):1026-34
pubmed: 21377654
Science. 1997 Aug 8;277(5327):812-4
pubmed: 9242609
J Neurosci. 2011 May 18;31(20):7533-9
pubmed: 21593338
Neuron. 2015 Jan 21;85(2):429-38
pubmed: 25611513
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
pubmed: 2899326
Elife. 2018 Oct 30;7:
pubmed: 30373717
Psychopharmacology (Berl). 2020 Dec;237(12):3553-3568
pubmed: 32778904
Curr Biol. 2022 Mar 14;32(5):1175-1188.e5
pubmed: 35134327
Brain Res. 1987 Aug 4;417(1):51-8
pubmed: 3040185
Addict Biol. 2023 Jan;28(1):e13247
pubmed: 36577719
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):757-62
pubmed: 26739562
Genes Brain Behav. 2012 Aug;11(6):704-11
pubmed: 22716474
Science. 2007 Oct 5;318(5847):71-6
pubmed: 17823315
Autism. 2020 May;24(4):899-918
pubmed: 32429819
Neuron. 2006 Sep 21;51(6):741-54
pubmed: 16982420
J Pharmacol Exp Ther. 1975 Jan;192(1):64-7
pubmed: 235638
Trends Pharmacol Sci. 2018 Mar;39(3):276-294
pubmed: 29338873
Psychopharmacology (Berl). 1991;104(1):6-16
pubmed: 1679242
Nat Neurosci. 2006 May;9(5):636-41
pubmed: 16582902
J Neurosci. 1993 Mar;13(3):1080-7
pubmed: 7680065
Hum Mol Genet. 2007 Dec 1;16(23):2880-91
pubmed: 17804423
Genesis. 2006 Aug;44(8):383-90
pubmed: 16865686
Nat Genet. 2003 May;34(1):27-9
pubmed: 12669065
Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):
pubmed: 31964652
J Neurosci. 2007 Sep 12;27(37):9817-23
pubmed: 17855595
Nat Neurosci. 2016 Jul;19(7):915-25
pubmed: 27239940
Neuron. 2013 Dec 18;80(6):1368-83
pubmed: 24360541
Pharmacol Biochem Behav. 2015 Jun;133:7-17
pubmed: 25812472
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
Cell. 2014 Jul 3;158(1):198-212
pubmed: 24995986
Nat Commun. 2018 Aug 9;9(1):3173
pubmed: 30093665
Biol Psychiatry. 2019 Dec 1;86(11):836-847
pubmed: 31471038
Neuron. 2008 Mar 13;57(5):760-73
pubmed: 18341995
J Physiol. 1987 Nov;392:397-416
pubmed: 2451725
J Neurosci. 1992 Feb;12(2):483-8
pubmed: 1346804
Autism Res. 2008 Jun;1(3):147-58
pubmed: 19360662